SEC Form 4 · accession 0001140361-15-037685
SYNERGETICS USA INC · SURG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert H Blankemeyer
Director
Period of report
Oct 15, 2015
Accepted (ET)
Oct 15, 2015 · 2:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000836429
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $3.46 | Oct 15, 2015 | D | 10,000 | D | — | Dec 13, 2023 | Common Stock | 10,000 | 0 | D |
| Stock option (right to buy)F1 | $3.70 | Oct 15, 2015 | D | 10,000 | D | — | Dec 12, 2024 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1Pursuant to the terms of the Agreement and Plan of Merger, dated as of September 1, 2015, by and among Valeant Pharmaceuticals International, Blue Subsidiary Corp. and Synergetics USA, Inc. (the "Merger Agreement"), on October 15, 2015, each option outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) was canceled in exchange for (i) a cash payment equal to the product of (A) the number of shares underlying the option and (B) the difference between $6.50, the cash consideration offered pursuant to the Merger Agreement, and the exercise price of the option; and (ii) one non-transferable contractual contingent value right per share underlying the option, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate, net to the holder in cash, upon the achievement of certain specified milestones within an agreed upon time period (less any applicable withholding taxes and without interest).